Celldex Therapeutics (NASDAQ: CLDX) — Company Overview, News & Financial Data
Cathay General Bancorp offers diverse financial services, aiming for sustainable growth and top-tier solutions for clients.
Celldex Therapeutics
Celldex Therapeutics (NASDAQ:CLDX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for cancer and other difficult-to-treat diseases. Drawing on a deep expertise in immunology, Celldex is pioneering a robust pipeline of potential therapies designed to enhance the body's natural defenses against disease. The company's projects span from early-stage research to phase 3 clinical trials, with key focuses on precision medicine and immune therapeutics. Through strategic collaborations and cutting-edge research, Celldex aims to improve patient outcomes and advance the field of medicine. Their objective is not only to deliver life-changing treatments to patients in need but also to lead the way in discovering and developing new pathways for treating cancer and immune-related diseases.
Snapshot
Operations
Products and/or services of Celldex Therapeutics
- CDX-0159: A monoclonal antibody targeting KIT for chronic inducible urticaria, currently in Phase 2 clinical trials.
- CDX-1140: An immune activating agonist targeting CD40, involved in Phase 1 trials for solid tumors and B-cell malignancies.
- CDX-527: A combination of an anti-PD-L1 and an anti-CD27 in one molecule, designed for various cancers, in Phase 1 trials.
- Glembatumumab vedotin: An antibody-drug conjugate targeting gpNMB for advanced melanoma and breast cancer, previously in clinical trials.
- Varlilumab: An agonist antibody targeting CD27 to activate the immune system against cancer, involved in clinical research.
- CDX-301: A recombinant human Flt3 ligand aimed at enhancing stem cell and immune restoration, used in various clinical settings.
Celldex Therapeutics executive team
- Anthony S. MarucciFounder, President, CEO & Director
- Tibor KelerFounder, Chief Scientific Officer & Executive VP
- Sam MartinSenior VP, CFO, Secretary & Treasurer
- Elizabeth CrowleyChief Product Development Officer & Senior VP
- Margo Heath-ChiozziSenior Vice President of Regulatory Affairs
- Joseph P. SchlessingerCo-Founder & Member of Scientific Advisory Board
- Sarah CavanaughSenior Vice President of Corporate Affairs & Administration
- Freddy A. JimenezSenior VP & General Counsel
- Ronald A. PepinChief Business Officer & Senior VP
- Diane C. YoungSenior VP & Chief Medical Officer
Latest news about Celldex Therapeutics
Key financials
Reported results for Celldex Therapeutics, in USD.
- Market cap
- 2.3B
- Revenue (TTM)
- 158K
- P/E ratio
- —
- EPS (diluted, TTM)
- -4.3
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 1.5M | -287.4M | -258.8M | |
| 7M | -195.1M | -157.9M | |
| 6.9M | -154.5M | -141.4M | |
| 2.4M | -115.2M | -112.3M |